CHAMPIONS ONCOLOGY, INC. (CSBR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31..
Quick ratio
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 18.73M USD | Liabilities, Current |
| Cash and equivalents | 4.36M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 13.60M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | (m) | $18.73M | $4.36M | (m) | $13.60M | (m) | (m) |
| 2026-04-30 | (m) | $19.92M | (m) | (m) | $13.18M | (m) | (m) |
| 2026-01-31 | (m) | $20.68M | $7.13M | (m) | $12.07M | (m) | (m) |
| 2025-10-31 | (m) | $22.14M | $8.52M | (m) | $11.54M | (m) | (m) |
| 2025-07-31 | (m) | $22.70M | $10.32M | (m) | $9.47M | (m) | (m) |
| 2025-04-30 | (m) | $23.85M | (m) | (m) | $11.23M | (m) | (m) |
| 2025-01-31 | (m) | $19.87M | $3.20M | (m) | $15.78M | (m) | (m) |
| 2024-10-31 | (m) | $18.86M | $2.75M | (m) | $10.47M | (m) | (m) |
| 2024-07-31 | (m) | $19.16M | $2.89M | (m) | $9.03M | (m) | (m) |
| 2024-04-30 | (m) | $21.54M | (m) | (m) | $9.53M | (m) | (m) |
| 2024-01-31 | (m) | $21.97M | $4.47M | (m) | $7.89M | (m) | (m) |
| 2023-10-31 | (m) | $20.95M | $5.51M | (m) | $7.72M | (m) | (m) |
| 2023-07-31 | (m) | $20.38M | $4.87M | (m) | $8.95M | (m) | (m) |
| 2023-04-30 | (m) | $21.73M | (m) | (m) | $8.01M | (m) | (m) |
| 2023-01-31 | (m) | $20.80M | $11.64M | (m) | $8.05M | (m) | (m) |
| 2022-10-31 | (m) | $18.74M | $10.83M | (m) | $8.95M | (m) | (m) |
| 2022-07-31 | (m) | $16.62M | $8.06M | (m) | $9.36M | (m) | (m) |
| 2022-04-30 | (m) | $17.48M | (m) | (m) | $9.51M | (m) | (m) |
| 2022-01-31 | (m) | $15.50M | $8.70M | (m) | $8.56M | (m) | (m) |
| 2021-10-31 | (m) | $12.46M | $4.78M | (m) | $8.19M | (m) | (m) |
| 2021-07-31 | (m) | $11.68M | $4.00M | (m) | $7.73M | (m) | (m) |
| 2021-04-30 | (m) | $11.20M | (m) | (m) | $6.99M | (m) | (m) |
| 2021-01-31 | (m) | $11.41M | $7.43M | (m) | $6.12M | (m) | (m) |
| 2020-10-31 | (m) | $12.75M | $8.55M | (m) | $5.96M | (m) | (m) |
| 2020-07-31 | (m) | $11.09M | $6.94M | (m) | $5.04M | (m) | (m) |
| 2020-04-30 | (m) | $12.09M | (m) | (m) | $4.77M | (m) | (m) |
| 2020-01-31 | (m) | $8.45M | $3.28M | (m) | $4.49M | (m) | (m) |
| 2019-10-31 | (m) | $8.25M | $2.78M | (m) | $3.92M | (m) | (m) |
| 2019-07-31 | (m) | $7.93M | $2.20M | (m) | $3.89M | (m) | (m) |
| 2019-04-30 | (m) | $8.03M | $3.24M | (m) | $4.38M | (m) | (m) |
| 2019-01-31 | (m) | $7.70M | $3.31M | (m) | $3.92M | (m) | (m) |
| 2018-10-31 | (m) | $7.33M | $2.00M | (m) | $4.70M | (m) | (m) |
| 2018-07-31 | (m) | $6.88M | $1.02M | (m) | $3.77M | (m) | (m) |
| 2018-04-30 | (m) | $7.45M | $856.00K | (m) | $3.92M | (m) | (m) |
| 2018-01-31 | (m) | $6.18M | $1.06M | (m) | $2.94M | (m) | (m) |
| 2017-10-31 | (m) | $5.82M | $660.00K | (m) | $2.58M | (m) | (m) |
| 2017-07-31 | (m) | $6.02M | $430.00K | (m) | $2.67M | (m) | (m) |
| 2017-04-30 | (m) | $7.45M | $3.29M | (m) | $2.27M | (m) | (m) |
| 2017-01-31 | (m) | $5.27M | $3.49M | (m) | $2.03M | (m) | (m) |
| 2016-10-31 | (m) | $4.60M | $4.33M | (m) | $1.89M | (m) | (m) |
| 2016-07-31 | (m) | $4.43M | $4.46M | (m) | $1.63M | (m) | (m) |
| 2016-04-30 | (m) | $5.31M | $2.58M | (m) | $1.31M | (m) | (m) |
| 2016-01-31 | (m) | $4.65M | $3.29M | (m) | $2.10M | (m) | (m) |
| 2015-10-31 | (m) | $3.27M | $4.16M | (m) | $1.89M | (m) | (m) |
| 2015-07-31 | (m) | $3.76M | $6.76M | (m) | $1.46M | (m) | (m) |
| 2015-04-30 | (m) | $3.80M | $9.36M | (m) | $1.06M | (m) | (m) |
| 2015-01-31 | (m) | $6.27M | $182.00K | (m) | $1.09M | (m) | (m) |
| 2014-10-31 | (m) | $3.94M | $575.00K | (m) | $1.11M | (m) | (m) |
| 2014-07-31 | (m) | $3.38M | $3.05M | (m) | $925.00K | (m) | (m) |
| 2014-04-30 | (m) | $3.66M | $5.89M | (m) | $1.32M | (m) | (m) |
| 2014-01-31 | (m) | $3.74M | $5.81M | (m) | $3.12M | (m) | (m) |
| 2013-10-31 | (m) | $3.27M | $7.57M | (m) | $1.46M | (m) | (m) |
| 2013-07-31 | (m) | $2.17M | $7.37M | (m) | $1.78M | (m) | (m) |
| 2013-04-30 | (m) | $2.93M | $9.56M | (m) | $500.00K | (m) | (m) |
| 2013-01-31 | (m) | $2.68M | $10.77M | (m) | $642.00K | (m) | (m) |
| 2012-10-31 | (m) | $2.93M | $2.16M | (m) | $627.00K | (m) | (m) |
| 2012-07-31 | (m) | $2.55M | $2.92M | (m) | $639.00K | (m) | (m) |
| 2012-04-30 | (m) | $3.49M | $4.75M | (m) | $584.00K | (m) | (m) |
| 2012-01-31 | (m) | $3.47M | $6.48M | (m) | $497.00K | (m) | (m) |
| 2011-10-31 | (m) | $3.42M | $7.12M | (m) | $832.00K | (m) | (m) |
| 2011-07-31 | (m) | $3.84M | $8.84M | (m) | $1.24M | (m) | (m) |
| 2011-04-30 | (m) | $3.50M | $10.46M | (m) | $585.00K | (m) | (m) |
| 2011-01-31 | (m) | (m) | $2.94M | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | $1.26M | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | $2.09M | (m) | (m) | (m) | (m) |
| 2010-04-30 | (m) | (m) | $2.57M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |